Evaxion A/s vs Roivant Sciences
Evaxion A/s and Roivant Sciences are similar in size: $7.5m and $8.3m of revenue in their latest fiscal years. Evaxion A/s grew faster (125.1% against -71.6%). Evaxion A/s kept more of each dollar of sales as profit: a net margin of -102.4% against -3629.2%. Roivant Sciences carries less debt relative to equity (0.0% against 32.5%).
| Latest fiscal year | Evaxion A/sEVAX, 2025 | Roivant SciencesROIV, 2026 |
|---|---|---|
| Revenue | $7.5m | $8.3m |
| Revenue growth | 125.1% | -71.6% |
| Net income | −$7.7m | −$300m |
| Operating margin | -122.7% | -6235.7% |
| Net margin | -102.4% | -3629.2% |
| Return on equity | -100.2% | -6.5% |
| Free cash flow | −$6.6m | −$759m |
| Cash | $23.2m | $1.42bn |
| Total debt | $5.5m | $0 |
| Debt to equity | 32.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 721 |
| Market value | $24.8m | $26.20bn |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 117 sales |